Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 3/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129242 | 0.98 | EBP (0.62) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL21674328 | 0.89 | EBP (0.53) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL10894213 | 0.89 | KDM4E (0.58) | EBPSIGMAR1HRH3KDM4E | |
| SCHEMBL11874283 | 0.89 | EBP (0.53) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL9706125 | 0.88 | EBP (0.72) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL3420518 | 0.81 | EBP (0.64) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL9773251 | 0.81 | HRH3 (0.61) | LTA4HHRH3KDM4E | |
| SCHEMBL4693255 | 0.79 | ESR1 (0.70) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL374223 | 0.79 | EBP (0.62) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL1985115 | 0.79 | EBP (0.62) | EBPSIGMAR1CYP2D6HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1569939-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004050660-A1 | NOVEL HETEROATOM CONTAINING TETRACYCLIC DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | EBP 696/4885SIGMAR1 466/4885CYP2D6 593/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | EBP 696/4885SIGMAR1 466/4885CYP2D6 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.